Pieris Pharmaceuticals wins award of “Pharma Trend – Image & Innovation Award”.
On September 14, the winners of the “Most Innovative Product” award in the category Leap Innovations were announced at the “Pharma Trend — Image & Innovation Award”. Formycon came out on top ahead of Ethris, with third place going to Pieris. The three Munich-based companies were each honored for the development of therapeutics against COVID-19. In addition, the winners of the “Golden Tablet” were chosen and the Pharma Trend Ranking with the best pharmaceutical companies was published.
For the first time this year, “The Most Innovative Product®” was chosen in the category Leap Innovations in collaboration with BioM. Companies that receive funding from the German Federal Ministry of Education and Research (BMBF) or the state of Bavaria to develop COVID-19 therapies in 2021 were eligible to apply.
Pieris Pharmaceuticals GmbH is a member of the Industrial Biotechnology Cluster and took third place with “Inhalable Anticalin® therapeutics for the treatment of SARS-CoV‑2 induced lung injury”. By way of background: A significant proportion of patients continue to suffer from severe impairment of lung function after acute COVID-19 disease due to severe damage to lung tissue.
Pieris’ project aims to treat such fibrotic damage to lung tissue. The inhalable Anticalin® drug candidate PRS-220 binds with high affinity to the protein Connective Tissue Growth Factor (CTGF). In parallel, PRS-220 is also being clinically developed for the treatment of idiopathic pulmonary fibrosis.